Whole-body metabolic connectivity framework with functional PET.
(18)F-fluorodeoxyglucose ((18)F-FDG)
Metabolic connectivity
Metabolic covariance
Network analysis
Whole-body PET
Journal
NeuroImage
ISSN: 1095-9572
Titre abrégé: Neuroimage
Pays: United States
ID NLM: 9215515
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
received:
16
09
2022
revised:
22
02
2023
accepted:
13
03
2023
medline:
7
4
2023
pubmed:
17
3
2023
entrez:
16
3
2023
Statut:
ppublish
Résumé
The nervous and circulatory system interconnects the various organs of the human body, building hierarchically organized subsystems, enabling fine-tuned, metabolically expensive brain-body and inter-organ crosstalk to appropriately adapt to internal and external demands. A deviation or failure in the function of a single organ or subsystem could trigger unforeseen biases or dysfunctions of the entire network, leading to maladaptive physiological or psychological responses. Therefore, quantifying these networks in healthy individuals and patients may help further our understanding of complex disorders involving body-brain crosstalk. Here we present a generalized framework to automatically estimate metabolic inter-organ connectivity utilizing whole-body functional positron emission tomography (fPET). The developed framework was applied to 16 healthy subjects (mean age ± SD, 25 ± 6 years; 13 female) that underwent one dynamic
Identifiants
pubmed: 36925087
pii: S1053-8119(23)00176-3
doi: 10.1016/j.neuroimage.2023.120030
pii:
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
120030Informations de copyright
Copyright © 2023. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, and Siemens Healthineers. R. Lanzenberger received travel grants and/or conference speaker honoraria from Bruker BioSpin within the last three years and investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. Ivo Rausch received a research grant from Siemens Healthineers not related to this study. All other authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.